One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Psychedelic-Assisted Psychotherapy and Carl Jung’s Red Book
James C. Harris, MD1
doi : 10.1001/jamapsychiatry.2021.1207
JAMA Psychiatry. 2021;78(8):815-816
Youth-Initiated Mentoring as a Scalable Approach to Addressing Mental Health Problems During the COVID-19 Crisis
Levi van Dam, PhD1; Jean Rhodes, PhD2; Renée Spencer, EdD3
doi : 10.1001/jamapsychiatry.2021.0490
JAMA Psychiatry. 2021;78(8):817-818
Cognitive Behavioral Therapy and the Implementation of Antiracism
Tashalee R. Brown, MD, PhD1; Kevin Y. Xu, MD, MPH1; Anne L. Glowinski, MD, MPE1,2
doi : 10.1001/jamapsychiatry.2021.0487
JAMA Psychiatry. 2021;78(8):819-820
Attenuated Psychosis Syndrome Should Be Moved to the Main Section in DSM-5-TR
Cheryl M. Corcoran, MD1,2; Vijay A. Mittal, PhD3; Scott W. Woods, MD4
doi : 10.1001/jamapsychiatry.2021.0838
JAMA Psychiatry. 2021;78(8):821-822
In Memoriam: James C. Harris, MD
Joseph T. Coyle, MD1; Dost ?ngür, MD, PhD2,3
doi : 10.1001/jamapsychiatry.2021.1318
JAMA Psychiatry. 2021;78(8):823
Equity and the JAMA Network
Phil B. Fontanarosa, MD, MBA1; Annette Flanagin, RN, MA2; John Z. Ayanian, MD, MPP3,4; Robert O. Bonow, MD, MS5,6; Neil M. Bressler, MD7,8; Dimitri Christakis, MD, MPH9,10; Mary L. Disis, MD11,12; S. Andrew Josephson, MD13,14; Melina R. Kibbe, MD15,16; Dost ?ngür, MD, PhD17,18; Jay F. Piccirillo, MD19,20; Rita F. Redberg, MD, MPH21,22; Frederick P. Rivara, MD, MPH23,24; Kanade Shinkai, MD, PhD25,26; Clyde W. Yancy, MD, MSc27,28
doi : 10.1001/jamapsychiatry.2021.1744
JAMA Psychiatry. 2021;78(8):824-826
Enhancing Prediction of Psychosis Risk With Cognitive Measures
James M. Gold, PhD1; Zachary B. Millman, PhD2,3; Dwight Dickinson, PhD, JD4
doi : 10.1001/jamapsychiatry.2021.0847
JAMA Psychiatry. 2021;78(8):827-828
Effect of Shamiri Layperson-Provided Intervention vs Study Skills Control Intervention for Depression and Anxiety Symptoms in Adolescents in Kenya
Tom L. Osborn, AB1,2,3; Katherine E. Venturo-Conerly, AB1,2,3; Susana Arango G., MA2; Elizabeth Roe, AB2; Micaela Rodriguez, AB2; Rediet G. Alemu, AB2; Jenny Gan, AB2; Akash R. Wasil, AB4; Benny H. Otieno, AB1,3; Thomas Rusch, PhD2,5; David M. Ndetei, DSc6,7; Christine Wasanga, PhD8; Jessica L. Schleider, PhD9; John R. Weisz, PhD2
doi : 10.1001/jamapsychiatry.2021.1129
JAMA Psychiatry. 2021;78(8):829-837
Low-cost interventions for adolescent depression and anxiety are needed in low-resource countries such as those in Sub-Saharan Africa.
Sustained Care Smoking Cessation Intervention for Individuals Hospitalized for Psychiatric Disorders
Richard A. Brown, PhD1; Haruka Minami, PhD2; Jacki Hecht, RN1; Christopher W. Kahler, PhD3,4; Lawrence H. Price, MD5,6; Kimberly L. Kjome, MD7,8; Erika Litvin Bloom, PhD9,10,11; Douglas E. Levy, PhD12,13; Kelly M. Carpenter, PhD14; Ashleigh Smith, LCSW15,16; Jasper A. J. Smits, PhD17; Nancy A. Rigotti, MD12
doi : 10.1001/jamapsychiatry.2021.0707
JAMA Psychiatry. 2021;78(8):839-847
Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia
Antonio Vita, MD, PhD1,2; Stefano Barlati, MD1,2; Anna Ceraso, MD1; Gabriele Nibbio, MD1; Cassandra Ariu, MOT2; Giacomo Deste, MD2; Til Wykes, DPhil3,4
doi : 10.1001/jamapsychiatry.2021.0620
JAMA Psychiatry. 2021;78(8):848-858
Cognitive impairment is a core feature of schizophrenia, with negative consequences on functional outcomes. Although cognitive remediation (CR) is effective and mentioned in treatment guidance for schizophrenia, its active ingredients and ideal candidates are still debated.
Neurocognitive Functioning in Individuals at Clinical High Risk for Psychosis
Ana Catalan, MD, PhD1,2,3,4; Gonzalo Salazar de Pablo, MD4,5,6; Claudia Aymerich, MD1; Stefano Damiani, MD7; Veronica Sordi, MD7; Joaquim Radua, MD, PhD4,8,9; Dominic Oliver, MSc4; Philip McGuire, MD, PhD10,11,12; Anthony J. Giuliano, PhD13; William S. Stone, PhD14; Paolo Fusar-Poli, MD, PhD4,7,10,12
doi : 10.1001/jamapsychiatry.2021.1290
JAMA Psychiatry. 2021;78(8):859-867
Neurocognitive functioning is a potential biomarker to advance detection, prognosis, and preventive care for individuals at clinical high risk for psychosis (CHR-P). The current consistency and magnitude of neurocognitive functioning in individuals at CHR-P are undetermined.
Continuation of Antidepressants vs Sequential Psychological Interventions to Prevent Relapse in Depression
Josefien J. F. Breedvelt, MSc1; Fiona C. Warren, PhD2; Zindel Segal, PhD3; Willem Kuyken, PhD4; Claudi L. Bockting, PhD5
doi : 10.1001/jamapsychiatry.2021.0823
JAMA Psychiatry. 2021;78(8):868-875
Depression frequently recurs. To prevent relapse, antidepressant medication is often taken in the long term. Sequentially delivering a psychological intervention while undergoing tapering of antidepressant medication might be an alternative to long-term antidepressant use. However, evidence is lacking on which patients may benefit from tapering antidepressant medication while receiving a psychological intervention and which should continue the antidepressant therapy. A meta-analysis of individual patient data with more power and precision than individual randomized clinical trials or a standard meta-analysis is warranted.
Suicide Risk in Medicare Patients With Schizophrenia Across the Life Span
Mark Olfson, MD, MPH1,2; T. Scott Stroup, MD, MPH1; Cecilia Huang, PhD3; Melanie M. Wall, PhD1,2; Stephen Crystal, PhD3; Tobias Gerhard, PhD3,4
doi : 10.1001/jamapsychiatry.2021.0841
JAMA Psychiatry. 2021;78(8):876-885
Although adults with schizophrenia have an increased risk of suicide, sample size limitations of previous research have hindered characterizations of suicide risk across the life span.
Racial/Ethnic, Social, and Geographic Trends in Overdose-Associated Cardiac Arrests Observed by US Emergency Medical Services During the COVID-19 Pandemic
Joseph Friedman, MPH1,2; N. Clay Mann, PhD, MS3; Helena Hansen, MD, PHD1; Philippe Bourgois, PhD1; Joel Braslow, MD, PhD1; Alex A. T. Bui, PhD2,4; Leo Beletsky, JD, MPH5,6,7; David L. Schriger, MD, MPH8
doi : 10.1001/jamapsychiatry.2021.0967
JAMA Psychiatry. 2021;78(8):886-895
Provisional records from the US Centers for Disease Control and Prevention (CDC) through July 2020 indicate that overdose deaths spiked during the early months of the COVID-19 pandemic, yet more recent trends are not available, and the data are not disaggregated by month of occurrence, race/ethnicity, or other social categories. In contrast, data from emergency medical services (EMS) provide a source of information nearly in real time that may be useful for rapid and more granular surveillance of overdose mortality.
Association of Childhood Adversities With Suicide Ideation and Attempts in Puerto Rican Young Adults
Lillian Polanco-Roman, PhD1,2; Kiara Alvarez, PhD3; Thomas Corbeil, MPH4; Pamela Scorza, PhD5; Melanie Wall, PhD4; Madelyn S. Gould, PhD, MPH2,4; Margarita Alegr?a, PhD3; Hector Bird, MD2; Glorisa J. Canino, PhD6; Cristiane S. Duarte, PhD, MPH2
doi : 10.1001/jamapsychiatry.2021.0480
JAMA Psychiatry. 2021;78(8):896-902
Racial/ethnic and sex disparities in suicide ideation and attempts are well established, with higher risk of suicide ideation and attempt among US racial/ethnic minority school-aged youths (than their White peers) and girls and women (than boys and men). The suicide-related risk of racial/ethnic minority young adults, especially young women, may be strongly influenced by adverse childhood experiences, known early determinants of suicide ideation and attempts.
Genetically Proxied Diurnal Preference, Sleep Timing, and Risk of Major Depressive Disorder
Iyas Daghlas, BS1,2; Jacqueline M. Lane, PhD1,2,3; Richa Saxena, PhD1,2,3; Céline Vetter, PhD1,4
doi : 10.1001/jamapsychiatry.2021.0959
JAMA Psychiatry. 2021;78(8):903-910
Morning diurnal preference is associated with reduced risk of major depressive disorder (MDD); however, causality in this association is uncertain.
Association of Mitochondrial Biogenesis With Variable Penetrance of Schizophrenia
Jianping Li, PhD1; Oanh T. Tran, BS2; T. Blaine Crowley, HS2; Tyler M. Moore, PhD3; Elaine H. Zackai, MD2,4; Beverly S. Emanuel, PhD2,4; Donna M. McDonald-McGinn, MS, CGC2,4; Raquel E. Gur, MD, PhD1,3; Douglas C. Wallace, PhD4,5; Stewart A. Anderson, MD1,3
doi : 10.1001/jamapsychiatry.2021.0762
JAMA Psychiatry. 2021;78(8):911-921
Discovery of mechanisms that underlie variable penetrance for neuropsychiatric illness in the context of genetic variants that carry elevated risk can advance novel treatment approaches for these disorders.
Considerations in Publishing a Psychiatric Randomized Clinical Trial With Kenyan Children
Dost ?ngür, MD, PhD1,2
doi : 10.1001/jamapsychiatry.2021.0926
JAMA Psychiatry. 2021;78(8):837-838
Use of Medications for Alcohol Use Disorder in the US
Beth Han, MD, PhD, MPH1; Christopher M. Jones, PharmD, DrPH, MPH2; Emily B. Einstein, PhD1; Patricia A. Powell, PhD3; Wilson M. Compton, MD, MPE1
doi : 10.1001/jamapsychiatry.2021.1271
JAMA Psychiatry. 2021;78(8):922-924
Challenges to Behavioral Health and Injury Surveillance During the COVID-19 Pandemic
Michael Schoenbaum, PhD1; Lisa Colpe, PhD, MPH1
doi : 10.1001/jamapsychiatry.2021.1201
JAMA Psychiatry. 2021;78(8):924-925
Challenges to Behavioral Health and Injury Surveillance During the COVID-19 Pandemic—Reply
Kristin M. Holland, PhD, MPH1; Alana M. Vivolo-Kantor, PhD, MPH1; Jennifer Adjemian, PhD2,3
doi : 10.1001/jamapsychiatry.2021.1204
JAMA Psychiatry. 2021;78(8):925-926
Errors in Statistical Results
doi : 10.1001/jamapsychiatry.2021.1374
JAMA Psychiatry. 2021;78(8):926
